Rectify Pharma touts positive data for clinical candidate RTY-406

US biotech Rectify Pharmaceuticals today announced the presentation of the discovery of RTY-406, the company’s clinical candidate, an oral, ABCB4 /BSEP dual-targeted PFM at the American Chemical Society Fall 2026 Meeting held August 22-27, 2026 in Chicago, USA.

The Boston-based biotechnology company is advancing positive functional modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function. It is the first company to directly address the untapped therapeutic potential of the ATP-binding cassette (ABC) transporter target class, a 48-member superfamily of membrane-bound proteins that actively export a diverse range of substrates across lipid membranes.